pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL
RIGEL PHARMACEUTICALS
RIGEL PHARMACEUTICALS INC
Rigel Pharmaceuticals is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker RIGL. Primary therapeutic focus areas include Rheumatoid Arthritis, Warm Antibody Autoimmune Hemoly
Company details
- Status
- Public
- HQ
- 1180 Veterans Blvd, South San Francisco, CA 94080, US
- Founded
- 1996
- Employees
- 286
- Programs
- 36
- Drugs
- 26
- Patents
- 373
Quick answer
Rigel Pharmaceuticals is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker RIGL. Primary therapeutic focus areas include Rheumatoid Arthritis, Warm Antibody Autoimmune Hemolytic Anemia, IGA Nephropathy, Acute Myeloid Leukemia, Ovarian Cancer. NovaPharmaNews links 36 clinical program(s), 3 drug profile(s), and 373 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (26), phase 1 (4), approved (3).
Company snapshot
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders and cancer.
- 4 approved product(s) across US/EU regulatory metadata.
- 36 active pipeline program(s) linked via ClinicalTrials.gov.
- 373 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for RIGEL PHARMACEUTICALS. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU
Recent coverage
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 2
Momentum
Proprietary activity score for RIGEL PHARMACEUTICALS.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for RIGEL PHARMACEUTICALS.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is RIGEL PHARMACEUTICALS?
-
Is RIGEL PHARMACEUTICALS publicly traded?
-
What drugs does RIGEL PHARMACEUTICALS develop or market?
-
What are the latest developments for RIGEL PHARMACEUTICALS?
-
What therapeutic areas does RIGEL PHARMACEUTICALS focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.